Souhaitez-vous accéder aux communiqués récents ?

Los Angeles, USA, March 17, 2021 (GLOBE NEWSWIRE) -- Celiac Disease Pipeline Insights: Analysis of Emerging Therapies, Key Pharma Players and Novel Approaches Celiac disease pipeline report...

Philadelphia, PA, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Beyond Celiac, the leading catalyst for a celiac disease cure in the United States, partnered with a record number of key biotechnology and...

Philadelphia, PA, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Beyond Celiac, the leading catalyst for a celiac disease cure in the United States, today announced it has been chosen by 9 Meters Biopharma, Inc....

Dublin, Sept. 28, 2020 (GLOBE NEWSWIRE) -- The "Celiac Disease (CD) - Market Insights, Epidemiology and Market Forecast- 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. ...

CeD LA 3001 trial doses first patient in historic Phase 3 celiac disease trial RALEIGH, N.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a...

Company is exploring potential strategic opportunities and non-dilutive sources of capital, and partnerships Continued activities of the first Phase 3 clinical trial for celiac disease including the...

Innovate undertakes succession planning for a chief executive officer Finance team strengthened and well positioned for future growth Second quarter earnings release expected August 8, 2019 ...

RALEIGH, N.C., June 24, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and...

RALEIGH, N.C., June 10, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and...

Analyst Meeting to be held at 4:30pm ET today to discuss NASH data and provide clinical updates Three posters presented at DDW 2019 highlighted the protective effect and molecular mechanism of action...